Skip to main content
. 2016 Mar 5;7(13):17103–17110. doi: 10.18632/oncotarget.7931

Figure 3. In vivo efficacy studies with gemcitabine and its EphA2-targetting-gemcitabne conjugates.

Figure 3

Each treated mice received the equivalent of 10 mg/Kg of Gemcitabine. (A) YNH-L2-Gemcitabine inhibits tumor growth in vivo to a greater extent as compared to Gemcitabine. Tumor volume is reported as calculated by caliper tumor measurement (blue diamonds, control; red squares, Gemcitabine; green circles, YNH-L2-GEM; violet triangles, YDH-L2-GEM); for statistical comparisons we used the two-way Anova analyses (GraphPad), ****p < 0.0001. (B) Bioluminescent tumor images taken for representative mice in each group at Day 34. Exposure time = 0.5 seconds. (C) In vivo efficacy studies with Gemcitabine and its 123B9-L2-Gem conjugate (blue diamonds, control; red squares, Gemcitabine; green circles, 123B9-L2-GEM) (D) Bioluminescent tumor images taken for representative mice in each group at day 33. Exposure time = 0.5 seconds.